lecanemab

Home
Ligands
lecanemab

GtoPdb Ligand ID: 12202

Synonyms: BAN-2401 | BAN2401 | lecanemab-irmb | Leqembi®

lecanemab is an approved drug (FDA (2023))

Comment: Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that targets amyloid β protein (APP) protofibrils [1,7]. It binds more potently to amyloid β protofibrils than to monomeric amyloid β [1,6]. Lecanemab was developed by Eisai and Biogen for potential to slow neurological decline in patients in the very early stages of developing Alzheimer's disease. It is not suitable for other forms of dementia.
This blog post by Derek Lowe ('Lecanemab and Alzheimer's: More Data'; posted on Nov. 30, 2022) provides a sound review of lecanemab's reported efficacy [8], what it contributes as an Alzheimer's therapy, and the issues around potential lecanemab-mediated cerebral bleeding events.

References
1. Gellerfors P, Lannfelt L, Sehlin D, Pettersson FE, Englund H. (2011) Protofibril selective antibodies and the use thereof. Patent number: US8025878B2. Assignee: Bioarctic Neuroscience AB. Priority date: 23/03/2006. Publication date: 27/09/2011.
2. Hoy SM. (2023) Lecanemab: First Approval. Drugs, 83 (4): 359-365. [PMID:36856953]
3. Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L. (2016) Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alzheimers Res Ther, 8 (1): 14. [PMID:27048170]
4. Roberts M, Sevastou I, Imaizumi Y, Mistry K, Talma S, Dey M, Gartlon J, Ochiai H, Zhou Z, Akasofu S et al.. (2020) Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun, 8 (1): 13. [PMID:32019610]
5. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A et al.. (2022) Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther, 14 (1): 70. [PMID:35598024]
6. Söllvander S, Nikitidou E, Gallasch L, Zyśk M, Söderberg L, Sehlin D, Lannfelt L, Erlandsson A. (2018) The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death. J Neuroinflammation, 15 (1): 98. [PMID:29592816]
7. Tucker S, Möller C, Tegerstedt K, Lord A, Laudon H, Sjödahl J, Söderberg L, Spens E, Sahlin C, Waara ER et al.. (2015) The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis, 43 (2): 575-88. [PMID:25096615]
8. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S et al.. (2022) Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine, Online ahead of print. DOI: 10.1056/NEJMoa2212948

References

1. Gellerfors P, Lannfelt L, Sehlin D, Pettersson FE, Englund H. (2011)
Protofibril selective antibodies and the use thereof.
Patent number: US8025878B2. Assignee: Bioarctic Neuroscience AB. Priority date: 23/03/2006. Publication date: 27/09/2011.

2. Hoy SM. (2023)
Lecanemab: First Approval.
Drugs, 83 (4): 359-365. [PMID:36856953]

3. Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L. (2016)
Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.
Alzheimers Res Ther, 8 (1): 14. [PMID:27048170]

4. Roberts M, Sevastou I, Imaizumi Y, Mistry K, Talma S, Dey M, Gartlon J, Ochiai H, Zhou Z, Akasofu S et al.. (2020)
Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease.
Acta Neuropathol Commun, 8 (1): 13. [PMID:32019610]

5. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A et al.. (2022)
Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Alzheimers Res Ther, 14 (1): 70. [PMID:35598024]

6. Söllvander S, Nikitidou E, Gallasch L, Zyśk M, Söderberg L, Sehlin D, Lannfelt L, Erlandsson A. (2018)
The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death.
J Neuroinflammation, 15 (1): 98. [PMID:29592816]

7. Tucker S, Möller C, Tegerstedt K, Lord A, Laudon H, Sjödahl J, Söderberg L, Spens E, Sahlin C, Waara ER et al.. (2015)
The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.
J Alzheimers Dis, 43 (2): 575-88. [PMID:25096615]

8. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S et al.. (2022)
Lecanemab in Early Alzheimer’s Disease.
New England Journal of Medicine, Online ahead of print. DOI: 10.1056/NEJMoa2212948